-
公开(公告)号：EP3508579A1
公开(公告)日：2019-07-10
申请号：EP18211761.4
申请日：2013-11-07
摘要： Provided herein are prokaryotic cells proficient to produce glycoconjugates in vivo, as well as methods for generating these cell and methods of using these cells to produce glycoconjugates. The compositions of the mentioned glycoconjugates as well as their different uses are also included.
-
公开(公告)号：EP3444352A3
公开(公告)日：2019-03-27
申请号：EP18198665.4
申请日：2013-11-07
摘要： Provided herein are prokaryotic cells proficient to produce glycoconjugates in vivo, as well as methods for generating these cell and methods of using these cells to produce glycoconjugates. The compositions of the mentioned glycoconjugates as well as their different uses are also included.
-
公开(公告)号：EP3427749A1
公开(公告)日：2019-01-16
申请号：EP18176145.3
申请日：2009-02-19
IPC分类号： A61K39/02 , A61K39/385 , A61K39/00 , A61K39/108 , A61K39/112 , A61K39/104 , C07K14/195
摘要： The present invention is directed to a bioconjugate vaccine such as an O1-bioconjugate vaccine, comprising: a protein carrier comprising an inserted consensus sequence, D/E - X - N - Z - S/T, wherein X and Z may be any natural amino acid except proline; and at least one antigenic polysaccharide from at least one bacterium, linked to the protein carrier, wherein the at least one antigenic polysaccharide is a bacterial O-antigen from one or more strain of Shigella, E. coli or Pseudomonas aeruginosa; and, optionally, an adjuvant. In another aspect of the present invention is directed to a method of producing a O1- bioconjugate in a bioreactor comprising a number of steps.
-
公开(公告)号：EP3527663A1
公开(公告)日：2019-08-21
申请号：EP19150645.0
申请日：2013-10-11
摘要： Described herein are novel methods of inserting nucleic acid sequences into host cells. Also described herein are genetically stable host cells comprising inserted nucleic acid sequences and methods of using such host cells in the generation of proteins.
-
公开(公告)号：EP3444352A2
公开(公告)日：2019-02-20
申请号：EP18198665.4
申请日：2013-11-07
摘要： Provided herein are prokaryotic cells proficient to produce glycoconjugates in vivo, as well as methods for generating these cell and methods of using these cells to produce glycoconjugates. The compositions of the mentioned glycoconjugates as well as their different uses are also included.
-
公开(公告)号：EP2566507B1
公开(公告)日：2017-11-22
申请号：EP11724567.0
申请日：2011-05-04
IPC分类号： A61K39/085
CPC分类号： A61K39/085 , A61K2039/505 , A61K2039/575 , A61K2039/6037 , A61K2039/6087 , A61K2039/64 , A61K2039/70 , C07K14/21 , C07K16/1271 , C07K2317/734 , C07K2319/00 , C07K2319/02 , C07K2319/034 , C07K2319/21 , C12N9/1029 , C12N9/1048 , C12N15/70 , C12N15/74 , Y02A50/47
摘要： An embodiment of the present invention is directed to a novel S. aureus bioconjugate vaccine. More generally, the invention is directed to Gram-positive and other bioconjugate vaccines comprising: a protein carrier comprising an inserted nucleic acid consensus sequence; at least one polysaccharide such as a capsular Gram-positive polysaccharide linked to the consensus sequence; and, optionally, an adjuvant or pharmaceutically acceptable carrier. In a further aspect, the instant invention is directed to methods of producing Gram-positive and other bioconjugate vaccines. In another aspect, an N- glycosylated protein is provided that comprises one or more polysaccharides such as Gram-positive polysaccharides. The present invention is additionally directed to engineered prokaryotic organisms comprising nucleotide sequences encoding a glycosyltransferase of a first prokaryotic organism and a glycosyltransferase of a second prokaryotic organism. The invention further includes plasmids and prokaryotic cells transformed with plasmids encoding polysaccharides and enzymes which produce an N- glycosylated protein and/or bioconjugate vaccine. Further, the invention is directed to methods of inducing an immune response in a mammal comprising administering said bioconjugate vaccines.
-
-
-
-
-
搜索结果
6 条记录 (耗时 0.016 秒)
